Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma
A new multiple myeloma drug combination shows comparable or better efficacy than current treatments for heavily pretreated patients with limited options remaining.
An indirect treatment comparison (GSK-sponsored) of belantamab mafodotin plus BortVD from the DREAMM-7 trial versus current standards of care in ≥3rd-line R/R multiple myeloma patients, concluding favorable efficacy for BelVd. This Letter provides ITC context for positioning belantamab mafodotin in the current MM treatment landscape.
What the study was
- Study design
- Indirect treatment comparison (network meta-analysis/ITC)
- Population
- 3rd-line or later R/R MM patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- American Journal of Hematology
Why it surfaced
Relevant belantamab mafodotin comparative data; Letter format limits score. GSK-sponsored ITC should be interpreted with awareness of industry funding.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.